Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy

Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that primarily causes neuronal and white matter injury and is among the leading cause of death among infants. Currently there are no well-established treatments; thus, it is important to understand the pathophysiology of the dis...

Full description

Bibliographic Details
Main Authors: Brandon J. Dixon, Cesar Reis, Wing Mann Ho, Jiping Tang, John H. Zhang
Format: Article
Language:English
Published: MDPI AG 2015-09-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/16/9/22368
id doaj-6a36cd6d9881434ea4d1bfe94356514b
record_format Article
spelling doaj-6a36cd6d9881434ea4d1bfe94356514b2020-11-25T00:46:41ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-09-01169223682240110.3390/ijms160922368ijms160922368Neuroprotective Strategies after Neonatal Hypoxic Ischemic EncephalopathyBrandon J. Dixon0Cesar Reis1Wing Mann Ho2Jiping Tang3John H. Zhang4Department of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USANeonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that primarily causes neuronal and white matter injury and is among the leading cause of death among infants. Currently there are no well-established treatments; thus, it is important to understand the pathophysiology of the disease and elucidate complications that are creating a gap between basic science and clinical translation. In the development of neuroprotective strategies and translation of experimental results in HIE, there are many limitations and challenges to master based on an appropriate study design, drug delivery properties, dosage, and use in neonates. We will identify understudied targets after HIE, as well as neuroprotective molecules that bring hope to future treatments such as melatonin, topiramate, xenon, interferon-beta, stem cell transplantation. This review will also discuss some of the most recent trials being conducted in the clinical setting and evaluate what directions are needed in the future.http://www.mdpi.com/1422-0067/16/9/22368neonatal hypoxic ischemic encephalopathyneuroprotectionintervention strategytherapeutic strategy
collection DOAJ
language English
format Article
sources DOAJ
author Brandon J. Dixon
Cesar Reis
Wing Mann Ho
Jiping Tang
John H. Zhang
spellingShingle Brandon J. Dixon
Cesar Reis
Wing Mann Ho
Jiping Tang
John H. Zhang
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
International Journal of Molecular Sciences
neonatal hypoxic ischemic encephalopathy
neuroprotection
intervention strategy
therapeutic strategy
author_facet Brandon J. Dixon
Cesar Reis
Wing Mann Ho
Jiping Tang
John H. Zhang
author_sort Brandon J. Dixon
title Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
title_short Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
title_full Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
title_fullStr Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
title_full_unstemmed Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
title_sort neuroprotective strategies after neonatal hypoxic ischemic encephalopathy
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2015-09-01
description Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that primarily causes neuronal and white matter injury and is among the leading cause of death among infants. Currently there are no well-established treatments; thus, it is important to understand the pathophysiology of the disease and elucidate complications that are creating a gap between basic science and clinical translation. In the development of neuroprotective strategies and translation of experimental results in HIE, there are many limitations and challenges to master based on an appropriate study design, drug delivery properties, dosage, and use in neonates. We will identify understudied targets after HIE, as well as neuroprotective molecules that bring hope to future treatments such as melatonin, topiramate, xenon, interferon-beta, stem cell transplantation. This review will also discuss some of the most recent trials being conducted in the clinical setting and evaluate what directions are needed in the future.
topic neonatal hypoxic ischemic encephalopathy
neuroprotection
intervention strategy
therapeutic strategy
url http://www.mdpi.com/1422-0067/16/9/22368
work_keys_str_mv AT brandonjdixon neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy
AT cesarreis neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy
AT wingmannho neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy
AT jipingtang neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy
AT johnhzhang neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy
_version_ 1725263786316660736